hello im a second year mbbs student. I have my pharmacology practical exam tomorrow. The topic is p drug. Prerapre a p drug list and drug of choice for parkinsonism
Reading File
Finding Sources
Finding Sources
Searching the Web
P drug selection Parkinson's disease pharmacology MBBS practical levodopa
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have all the information needed. Let me compile a comprehensive P-drug practical answer for the MBBS student.
P-Drug List & Drug of Choice for Parkinsonism
Pharmacology Practical — MBBS Format
What is a P-Drug?
A P-drug (Personal Drug) is the drug you, as a clinician, choose for a specific condition based on four criteria:
Efficacy → Safety → Suitability → Cost (ESSC)
Pathophysiology (Essential Background)
Parkinsonism results from degeneration of dopaminergic neurons in the substantia nigra (pars compacta), leading to:
- ↓ Dopamine in the nigrostriatal pathway
- Relative excess of acetylcholine activity in the basal ganglia
Cardinal features: Tremor (resting, pill-rolling) · Rigidity · Akinesia/Bradykinesia · Postural instability (TRAP)
Drug Classes for Parkinsonism
1. Dopamine Precursor (Gold Standard)
| Drug | Mechanism | Notes |
|---|---|---|
| Levodopa | Crosses BBB → converted to dopamine in CNS by DOPA decarboxylase | Never given alone in modern practice |
| Levodopa + Carbidopa (Sinemet) | Carbidopa = peripheral DOPA decarboxylase inhibitor → prevents peripheral conversion → ↑ CNS bioavailability, ↓ dose needed, ↓ GI/cardiac side effects | Standard first-line |
| Levodopa + Entacapone (Stalevo) | Entacapone = COMT inhibitor → prolongs levodopa effect | Used for wearing-off |
Adverse effects of Levodopa: Nausea/vomiting, postural hypotension, dyskinesias (dose-related), on-off phenomenon, wearing-off, psychiatric disturbances (hallucinations)
2. Dopamine Agonists
| Drug | Receptor | Notes |
|---|---|---|
| Pramipexole | D₃ agonist (non-ergot) | Used as initial monotherapy (esp. in younger patients) or adjunct; causes impulse control disorders, somnolence |
| Ropinirole | D₂ agonist (non-ergot) | Similar to pramipexole |
| Bromocriptine | D₂ agonist (ergot) | More toxic; rarely used now |
| Apomorphine | Non-ergot, SC route | Rescue therapy for levodopa-induced dyskinesias |
3. MAO-B Inhibitors
| Drug | Mechanism | Notes |
|---|---|---|
| Selegiline | Selective MAO-B inhibitor → ↓ dopamine breakdown | Early/mild PD; adjunct to levodopa; possible neuroprotective effect |
| Rasagiline | Selective MAO-B inhibitor (more potent than selegiline) | Adjunct; caution: serotonin syndrome with meperidine/SSRIs |
| Safinamide | MAO-B inhibitor | Adjunct for response fluctuations |
4. COMT Inhibitors
| Drug | Mechanism | Notes |
|---|---|---|
| Entacapone | Peripheral COMT inhibitor → prolongs levodopa action | Always used with levodopa; ↑ levodopa toxicity risk |
| Tolcapone | Central + peripheral COMT inhibitor | Risk of hepatotoxicity — monitor LFTs |
| Opicapone | Once-daily peripheral COMT inhibitor | Newer agent |
5. Antimuscarinic (Anticholinergic) Agents
| Drug | Mechanism | Notes |
|---|---|---|
| Trihexyphenidyl (Benzhexol) | Central M-receptor antagonist | Best for tremor & rigidity; minimal effect on bradykinesia |
| Benztropine | Central M-receptor antagonist | Also used for drug-induced parkinsonism |
| Biperiden | Central M-receptor antagonist | Similar to benztropine |
Adverse effects: Dry mouth, blurred vision, urinary retention, constipation, sedation, confusion (especially in elderly)
Indication: Mainly for tremor-dominant PD in younger patients or drug-induced parkinsonism
6. NMDA Antagonist
| Drug | Mechanism | Notes |
|---|---|---|
| Amantadine | Weak NMDA-glutamate receptor antagonist; may also release stored dopamine | Early/mild PD; also used for levodopa-induced dyskinesias; adverse effects: leg edema, livedo reticularis |
P-Drug Selection for Parkinsonism
Using ESSC criteria:
| Criterion | Levodopa + Carbidopa |
|---|---|
| Efficacy | Most efficacious — ameliorates ALL motor symptoms (tremor, rigidity, bradykinesia) |
| Safety | Well-characterized; manageable side effects; dyskinesias with long-term use |
| Suitability | Suitable for most patients; caution in younger patients (early motor fluctuations) |
| Cost | Inexpensive, widely available |
✅ P-Drug (Drug of Choice) for Parkinsonism
Levodopa + Carbidopa (co-careldopa / Sinemet)
Why not levodopa alone? Carbidopa inhibits peripheral decarboxylation, reducing the dose of levodopa needed by ~75%, and dramatically reduces peripheral side effects (nausea, cardiac arrhythmias).
Special Situations
| Situation | Preferred Drug |
|---|---|
| Elderly patient, all symptoms | Levodopa + Carbidopa |
| Young patient, early/mild PD | Dopamine agonist (pramipexole/ropinirole) — delays levodopa motor complications |
| Tremor-dominant, young patient | Trihexyphenidyl (anticholinergic) |
| Drug-induced parkinsonism | Stop offending drug; Benztropine if needed |
| Early mild PD, possible neuroprotection | Selegiline / Rasagiline |
| Wearing-off phenomenon | Add Entacapone (COMT inhibitor) or MAO-B inhibitor |
| Levodopa-induced dyskinesias | Amantadine (rescue: Apomorphine SC) |
Quick Recall Summary Table
| Class | Key Drug | Mechanism |
|---|---|---|
| Dopamine precursor | Levodopa + Carbidopa ⭐ | ↑ CNS dopamine |
| Dopamine agonist | Pramipexole, Ropinirole | Direct D₂/D₃ stimulation |
| MAO-B inhibitor | Selegiline, Rasagiline | ↓ Dopamine breakdown |
| COMT inhibitor | Entacapone | Prolong levodopa action |
| Anticholinergic | Trihexyphenidyl, Benztropine | Correct DA/ACh imbalance |
| NMDA antagonist | Amantadine | Weak glutamate block |
Sources: Katzung's Basic and Clinical Pharmacology 16e; Goodman & Gilman's Pharmacological Basis of Therapeutics; Swanson's Family Medicine Review; Adams and Victor's Principles of Neurology 12e
Good luck in your practical exam tomorrow! 🎯
hello im a second year mbbs student. I have my pharmacology practical exam tomorrow. The topic is p drug. Prerapre a p drug list and drug of choice for shigellosis
Finding Sources
Finding Sources
Searching the Web
shigellosis drug of choice 2024 WHO treatment guidelines ciprofloxacin azithromycin
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
I now have all the information needed from authoritative sources. Let me compile the comprehensive P-drug practical answer.
P-Drug List & Drug of Choice for Shigellosis
Pharmacology Practical — MBBS Format
What is a P-Drug?
A P-drug (Personal Drug) is the drug you personally select for a specific condition based on four criteria:
Efficacy → Safety → Suitability → Cost (ESSC)
Background: Shigellosis
Causative organism: Shigella species (Gram-negative, non-motile, non-spore-forming bacilli)
- S. dysenteriae (Type 1 — most severe, produces Shiga toxin, epidemic)
- S. flexneri (dominant in developing countries)
- S. boydii
- S. sonnei (dominant in developed countries, ~85% of US cases — mildest)
Transmission: Feco-oral route — "4 F's": Food, Fingers, Feces, Flies. Very low infectious dose (10–100 organisms).
Clinical features: Fever + cramping abdominal pain + bloody mucoid diarrhea (bacillary dysentery) — classic presentation
Pathogenesis: Shigella invades intestinal epithelial cells → intracellular replication → cell death → ulceration → bloody diarrhea. S. dysenteriae also produces Shiga toxin (inhibits protein synthesis via 28S rRNA cleavage).
Key Principle Before Drug Selection
Shigellosis is a self-limited illness in most immunocompetent adults (resolves in 5–7 days without treatment). However, antibiotic treatment is recommended because it:
- Shortens illness duration
- Reduces complications and mortality
- Eliminates Shigella from stools → prevents secondary spread (public health)
⚠️ Antidiarrheal drugs (loperamide, opioids) are CONTRAINDICATED — they worsen symptoms and may prolong infection.
Drug Classes for Shigellosis
1. Fluoroquinolones (First-Line)
| Drug | Dose | Duration |
|---|---|---|
| Ciprofloxacin ⭐ | Adults: 500 mg PO BD | 3 days (non-dysenteriae); 5 days (S. dysenteriae); 7–10 days (immunocompromised) |
| Children: 15 mg/kg PO BD (max 1 g/day) | ||
| Norfloxacin | 400 mg PO BD | 3–5 days |
Mechanism: Inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV → disruption of DNA replication and transcription → bactericidal
Spectrum: Excellent activity against gram-negative enteric pathogens including Shigella
Adverse effects: GI upset, photosensitivity, tendinopathy/tendon rupture (Achilles), QT prolongation, avoid in children/pregnancy (theoretical cartilage damage — but accepted indication for shigellosis in children)
Resistance concern: CDC has reported emerging ciprofloxacin resistance (~1.6–5% of strains); extensively drug-resistant strains increasing since 2022
2. Macrolides (Alternative First-Line / Resistant Cases)
| Drug | Dose | Duration |
|---|---|---|
| Azithromycin | Adults: 1–1.5 g PO once daily | 1–5 days |
| Children: 6–20 mg/kg PO once daily |
Mechanism: Binds to 50S ribosomal subunit → inhibits translocation of peptidyl-tRNA → blocks protein synthesis → bacteriostatic (bactericidal at high concentrations)
Use: Particularly useful for antibiotic-resistant Shigella infections in adults and children; also used in pregnancy (safe alternative)
Adverse effects: GI upset, QT prolongation, hepatotoxicity (rare), drug interactions (CYP3A4)
3. 3rd Generation Cephalosporins (Parenteral / Children)
| Drug | Dose | Route | Duration |
|---|---|---|---|
| Ceftriaxone | Children: 50–100 mg/kg once daily; Adults: 1–2 g once daily | IM/IV | 2–5 days |
Mechanism: Beta-lactam → inhibits penicillin-binding proteins (PBPs) → disrupts peptidoglycan cross-linking → bactericidal
Use: Severe infections, patients unable to take oral medications, pregnant women (ciprofloxacin contraindicated), children with severe disease
4. Ampicillin-Group β-Lactams (Now Mostly Obsolete)
| Drug | Notes |
|---|---|
| Ampicillin | Used historically; now >59% resistance — not recommended empirically |
| Amoxicillin | Similar resistance pattern; avoid empirically |
5. Cotrimoxazole / TMP-SMX (Obsolete for Empiric Use)
| Drug | Notes |
|---|---|
| TMP-SMX (Cotrimoxazole) | Previously first-line; now >43% resistance — NOT recommended for empiric treatment; use only if sensitivity confirmed |
Mechanism (historical knowledge): TMP inhibits dihydrofolate reductase + SMX inhibits dihydropteroate synthase → sequential block of folate synthesis → bactericidal
6. Pivmecillinam (Second-Line, Limited Availability)
| Drug | Dose | Notes |
|---|---|---|
| Pivmecillinam | Adults: 400 mg PO QID × 5 days | No pediatric formulation; expensive; not widely available in India |
P-Drug Selection: ESSC Analysis
| Criterion | Ciprofloxacin | Azithromycin | Ceftriaxone |
|---|---|---|---|
| Efficacy | ✅ Most validated; fastest clinical improvement | ✅ Effective, especially for resistant strains | ✅ Effective but mostly IM/IV |
| Safety | ✅ Well-characterised; avoid in pregnancy | ✅ Safe in pregnancy | ✅ Safe in pregnancy & children |
| Suitability | ✅ Oral, available; not in pregnancy | ✅ Oral; good for resistance | ❌ Must be injected |
| Cost | ✅ Inexpensive, widely available | ✅ Moderately priced | ❌ Higher cost, hospital-based |
✅ P-Drug (Drug of Choice) for Shigellosis
Ciprofloxacin — 500 mg PO twice daily × 3 days (adults)
Why Ciprofloxacin?
- Highest clinical evidence base as first-line (WHO, Harrison's, CDC)
- Oral bioavailability (~70–80%), excellent tissue penetration
- Active against all Shigella species
- Short 3-day course → good compliance, low cost
- Bactericidal → reduces shedding, prevents spread
Special Situations Summary
| Situation | Drug of Choice |
|---|---|
| Uncomplicated adult shigellosis | Ciprofloxacin 500 mg BD × 3 days |
| Children | Ciprofloxacin 15 mg/kg BD × 3 days OR Ceftriaxone IM |
| Pregnancy | Ceftriaxone IM (ciprofloxacin avoided) OR Azithromycin |
| Severe infection / unable to take oral | Ceftriaxone IV/IM |
| S. dysenteriae type 1 | Ciprofloxacin × 5 days |
| Immunocompromised | Ciprofloxacin × 7–10 days |
| Ciprofloxacin-resistant strain | Azithromycin |
| Confirmed TMP-SMX sensitive strain | Cotrimoxazole (cheap, oral) |
| Drug-induced diarrhea worsening | STOP antidiarrheals (loperamide — contraindicated) |
Quick Recall Table — All Drug Options
| Class | Drug | Mechanism | Status |
|---|---|---|---|
| Fluoroquinolone | Ciprofloxacin ⭐ | DNA gyrase + topoisomerase IV inhibition | First-line |
| Macrolide | Azithromycin | 50S ribosome → ↓ protein synthesis | Alternative/resistant strains |
| 3rd-gen cephalosporin | Ceftriaxone | PBP inhibition → cell wall lysis | Parenteral/severe/children |
| β-lactam | Ampicillin | PBP inhibition | ❌ High resistance — obsolete |
| Sulfonamide combination | TMP-SMX | Folate synthesis block (dual) | ❌ High resistance — avoid empirically |
| Aminopenicillin | Pivmecillinam | PBP inhibition | Second-line, limited availability |
Supportive Treatment (Don't Forget!)
- Oral Rehydration Therapy (ORT) — mainstay of management
- IV fluids — if severe dehydration or unable to take orally
- No antidiarrheals (loperamide, codeine) — contraindicated
- No antispasmodics — may worsen clinical course
- Antipyretics (paracetamol) for fever
Sources: Harrison's Principles of Internal Medicine 22e (Table 172-1); Jawetz, Melnick & Adelberg's Medical Microbiology 28e; Katzung's Basic and Clinical Pharmacology 16e; WHO Guidelines for Control of Shigellosis; CDC Advisory (2023)
Best of luck for your exam tomorrow! 🎯
hello im a second year mbbs student. I have my pharmacology practical exam tomorrow. The topic is p drug. Prerapre a p drug list and drug of choice for Typhoid fever
Finding Sources
Finding Sources
Searching the Web
typhoid fever drug of choice 2024 WHO treatment guidelines fluoroquinolone azithromycin ceftriaxone MBBS
You've run out of free credits. Sign up for a free account to continue using Orris.
This is a shared conversation. Sign in to Orris to start your own chat.